The iLet is a closed-loop, fully integrated BP platform. The iLet bionic pancreas (BP)¹ significantly increased the percentage of time adults with type 1 diabetes (T1D) had glucose levels between 70–180 mg/dl, when compared to usual care (UC) therapy of either multiple daily insulin injections (MDI) or continuous subcutaneous insulin infusion (CSII), according to the study, “First Human Study Testing the iLet, a Purpose-Built Bionic Pancreas Platform,” presented today at the American Diabetes Association’s® (ADA’s) 79th Scientific Sessions® at the Moscone Convention Center in San Francisco. Study presented at ADA’s Scientific Sessions compared insulin-only mode of iLet to usual care
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |